CYP2D6, serotonin, and suicidea relationship?

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 3, 2010, Pages 304-305

  Bertilsson, L ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYINDOLEACETIC ACID; CYTOCHROME P450 2D6; NEUROLEPTIC AGENT; SEROTONIN; SEROTONIN UPTAKE INHIBITOR;

DEPRESSION; DRUG METABOLISM; GENE; GENE FREQUENCY; GENOTYPE; HUMAN; PHENOTYPE; PRIORITY JOURNAL; SHORT SURVEY; SUICIDE; CAUSE OF DEATH; CEREBROSPINAL FLUID; GENE DUPLICATION; GENETICS; METABOLISM; NOTE; SUICIDE ATTEMPT;

CAUSE OF DEATH; CYTOCHROME P-450 CYP2D6; GENE DUPLICATION; HUMANS; HYDROXYINDOLEACETIC ACID; SEROTONIN; SUICIDE; SUICIDE, ATTEMPTED;

EID: 77955872795     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.144     Document Type: Short Survey

References (14)

1. Träskman, L., Åsberg, M., Bertilsson, L. & Sjöstrand, L. Monoamine metabolites in CSF and suicidal behaviour. Arch. Gen. Psychiatr. 38, 631-636 (1981).
2. Lester, D. The concentration of neurotransmitter metabolites in the cerebrospinal fluid of suicidal individuals: a meta-analysis. Pharmacopsychiatry 28, 45-50 (1995).
3. Isacsson, G., Holmgren, A., Osby, U. & Ahlner, J. Decrease in suicide among the individuals treated with antidepressants: a controlled study of antidepressants in suicide, Sweden 1995-2005. Acta Psychiatr. Scand. 120, 37-44 (2009).
4. Zackrisson, A.L., Lindblom, B. & Ahlner, J. High frequency of occurrence of CYP2D6 gene Duplication/multiduplication indicating ultrarapid metabolism among suicide cases. Clin. Pharmacol. Ther. 88, 354-359 (2010).
5. Bertilsson, L. Metabolism of antidepressant and neuroleptic drugs by cytochrome P450s: clinical and interethnic aspects. Clin. Pharmacol. Ther. 82, 606-609 (2007).
6. Kawanishi, C., Lundgren, S., Ågren, H. & Bertilsson, L. Increased incidence of CYP2D6 gene duplication in patients with persistent mood disorders: ultrarapid metabolism of antidepressants as a cause of nonresponse. A pilot study. Eur. J. Clin. Pharmacol. 59, 803-807 (2004).
7. Rau, T. et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants\a pilot Study. Clin. Pharmacol. Ther. 75, 386-393 (2004).
8. Bertilsson, L., Alm, C., De Las Carreras, C., Widen, J., Edman, G. & Schalling, D. Debrisoquine hydroxylation polymorphism and personality [letter]. Lancet 1, 555 (1989).
9. González, I., Peñas-Lledó, E.M., Pérez, B., Dorado, P., Alvarez, M. & LLerena, A. Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers. Pharmacogenomics 9, 833-840 (2008).
10. Niznik, H.B. et al. The dopamine transporter and cytochrome P45OIID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins. Arch. Biochem. Biophys. 276, 424-432 (1990).
11. Siegle, I., Fritz, P., Eckhardt, K., Zanger, U.M. & Eichelbaum, M. Cellular localization and regional distribution of CYP2D6 mRNA and protein expression in human brain. Pharmacogenetics 11, 237-245 (2001).
12. Eichelbaum, M. In search of endogenous CYP2D6 substrates. Pharmacogenetics 13, 305-306 (2003).
13. Yu, A.M., Idle, J.R., Byrd, L.G., Krausz, K.W., Kupfer, A. & Gonzalez, F.J. Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics 13, 173-181 (2003).
14. Kirchheiner, J. et al. Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets. Pharmacogenet. Genomics 15, 579-587 (2005).